In a phase 3 trial published Oct. 23, 2026, in JAMA, women with HER2-low metastatic breast cancer went a median 16.4 months without progression on trastuzumab rezetecan vs. 6.8 months on chemotherapy,…
In a study of 75 women with breast cancer published Oct. 26, 2026, in Brain, Behavior, and Immunity, worse sleep during chemotherapy predicted more self-reported thinking problems about three months later, and…
A network meta-analysis published Oct. 1, 2026, in JAMA Network Open linked risk-reducing mastectomy to lower all-cause mortality than MRI-based screening (hazard ratio 0.37) in women with BRCA1 or BRCA2 variants, though…
Five-year results of the PHERGain trial, published Oct. 29, 2026, in Nature Medicine, show that 89.5% of women on a PET-guided plan were free of invasive disease, and 92.4% of those who…
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with HR+/HER2- breast cancer that had progressed after hormone therapy, CDK4/6 inhibitors and chemotherapy went a median 8.2 months…
In a phase 3 trial in China published Oct. 24, 2026, in NEJM, 58.5% of women with HER2-positive advanced breast cancer on anbenitamab plus a docetaxel formulation were free of progression at…
